XNAS · Healthcare · Biotechnology
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | -0.26 | 0.25 | +196.15% | $106.7M | ✅ Beat | +1.59% | -5.79% | — |
| 2026-02-25 | Q4 2025 | -0.23 | -0.60 | -160.87% | $104.5M | ❌ Miss | -3.50% | +4.88% | -8.46% |
| 2025-11-06 |
| Q3 2025 |
| -0.26 |
| 0.00 |
| +100.00% |
| $103.7M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-02-26 | Q4 2024 | -0.24 | -0.47 | -95.83% | $84.1M | ❌ Miss | -3.87% | -1.69% | -3.87% |
| 2024-05-08 | Q1 2024 | -0.36 | -0.49 | -36.11% | $70.5M | ❌ Miss | -2.40% | -8.66% | -32.03% |
| 2024-02-28 | Q4 2023 | -0.28 | -0.40 | -42.86% | $70.2M | ❌ Miss | — | — | — |
| 2023-11-07 | Q3 2023 | -0.33 | 0.04 | +112.12% | $62.9M | ✅ Beat | +2.45% | -3.37% | +9.51% |
| 2023-08-10 | Q2 2023 | -0.41 | -0.37 | +9.76% | $60.7M | ✅ Beat | +0.37% | -5.47% | -9.68% |
Showing last 8 quarters.